Navigation Links
Tel Aviv Stock Exchange Weekly Review: 18-22 August 2013
Date:8/22/2013

TEL AVIV, Israel, August 22, 2013 /PRNewswire/ --

Biomed company, OPKO Health, dual listed on TASE. Trading has started and it is anticipated that OPKO shares will join the TA-25 and TA BlueTech-50 indices in October;  Trading on the Tel-Aviv Stock Exchange (TASE) during the third week of August was marked by mixed trending in all leading indices.

     (Logo: http://photos.prnewswire.com/prnh/20130117/588933)

TA-25

The TA-25 index decreased 0.3% over the week, bringing year-to-date increase to 1.3%.

TA-100

The TA-100 index decreased 0.4% over the week, bringing year-to-date increase to 4.4%.

TA-Biomed

The TA-Biomed index stood out and increased 4.2% over the week and bringing returns since the beginning of 2013 to 24%.

Dual Listings

OPKOHealth, whose shares are traded on the NYSE, completed a dual listing of its share on TASE, starting 21 August, 2013. OPKO is an American company which invests in bio-pharma and diagnostic R&D firms.

Having a market cap of US $2.8 billion, it is anticipated that the company's shares will be "fast tracked" on to the TA-25 and TA BlueTech-50 indices this coming October.

Corporate Bonds

Three real estate companies raised US$62 million in public bond offerings.

Since the beginning of the year the business sector has raised US $6.5 billion through bond offerings. Real estate companies stood out, raising 43% of the total

Government Bonds

This week the Ministry of Finance (MoF) floated US $0.3 billion government bonds in an offering on the local market.  

Since the beginning of 2013 the MoF raised US $12.3 billion in public bond offerings as opposed to US $21.3 billion in 2012.

Growth Rate

Figures released by the Central Bureau of Statistics indicate that economic growth came to 5.1% (annualized) in the second quarter of 2013, compared to 2.7
'/>"/>

SOURCE Tel Aviv Stock Exchange Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMed Realty Trust Declares Fourth Quarter 2011 Common Stock and Preferred Stock Dividends
2. Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
3. Soligenix Announces 1 for 20 Reverse-Split of its Common Stock
4. Medisafe 1 Technologies to Start the $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share
5. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
6. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
7. Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants
8. Generex Announces Date of Annual Stockholders Meeting
9. Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock
10. BioMed Realty Trust Declares Second Quarter 2012 Common Stock And Preferred Stock Dividends
11. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in whole ... to do so would constitute a violation of the relevant ... the "Company") (LSE: SHP, NASDAQ: SHPG ) notes ... a meeting with representatives of AbbVie. This statement ... approval of AbbVie. A further update will be ...
(Date:7/11/2014)... 11, 2014  Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/10/2014)... Understanding the need for better quality ... the gap that currently exists in this area, ChanTest ... portfolio of validated ion channel and GPCR cell lines. ... as ion channels control many critical physiological functions throughout ... the potential to treat a variety of human diseases. ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... BEIJING , June 1 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... and,sale of medical products in China , said today that it ... anesthesia product manufactured,by Penlon, a UK firm specializing in anesthesia and breathing ... , ...
... -- Pioneer Surgical Technology, Inc. is pleased to announce that the ... study patients was presented at the recent 10th annual meeting of The ... Orleans by Domagoj Coric , M.D., Chief, Department of Neurosurgery, ... , ...
... June 1 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... has received approval from the Belgian Federal Agency for ... 3 trial examining REOLYSIN in combination with paclitaxel and ... This is the same trial that was agreed to ...
Cached Biology Technology:Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 2Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 3Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 4Two-Year Follow up Data of NuBac® IDE Feasibility Study Was Presented at SAS Meeting 2Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
(Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... This news release is available in ... November 26, 2013 In the developing world, Cryptosporidium ... decade ago, it announced its presence in the United States, ... the county,s history. Its rapid ability to spread, combined with ...
... new study reveals how pollution causes thunderstorms to leave ... Proceedings of the National Academy of Sciences ... reveal how pollution plays into climate warming. The work ... weather and climate models. Researchers had thought that ...
... mild cognitive impairment is a transitional stage between ... networks during this transformation have yet to be ... University of Technology, China constructed brain networks using ... four populations (normal controls, patients with early mild ...
Cached Biology News:Treatment target identified for a public health risk parasite 2The lingering clouds 2The lingering clouds 3
... GenePix Pro is the industry standard ... unique combination of imaging and analysis tools, ... use. GenePix Pro is included with every ... images from third-party scanners and all types ...
... the one mouse-click image analysis software ... It is the solution for high ... images. MicroVigene is empowered with VigeneTechs ... grid, regional 2D-curve fitting background correction ...
... For applications not requiring confocal, the ... alternative to the Pathway 435. And, the ... if later applications require it. ... can elect to use the laser autofocus, ...
... Proteomic Imaging System, Professional Package Superior ... Dynamic Range: The ProXPRESS 2D Proteomic Imaging ... system for both proteomic and general life ... flexibility, enabling the use of all dyes ...
Biology Products: